News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Primo Brands shows operational stabilization after last year's merger disruptions.
  • Investor positioning has improved and the company continues a steady dividend.
  • Primo's top-line run rate is elevated but improving, offering potential for margin leverage.
  • Zeta Global reported $442.8 million revenue, up 43.5% year-over-year.
  • Zeta raised full-year revenue guidance to roughly $1.82 billion.
  • Zeta's free cash flow topped $214 million, though valuation multiple compression remains a risk.

Latest Articles

Ligand to Participate in September Investor Conferences

Ligand to Participate in September Investor Conferences

Ligand Pharmaceuticals announced that its senior management team will participate in key investor conferences in September 2026, including the Wells Fargo Healthcare Conference, Citi Biopharma Back to School Conference, and H.C. Wainwright Global Investment Conference. Management will conduct fireside chats and one-on-one meetings to discuss the co…

Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid Tumors

Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid Tumors

Radiopharm Theranostics has dosed the first patient in the second cohort of its Phase 1/2a clinical trial for RV-01 (177Lu-Betabart), a radiopharmaceutical targeting B7-H3 expressing solid tumors. The trial aims to evaluate safety, biodistribution, and preliminary anti-tumor efficacy, progressing after a positive safety recommendation. This marks a…

Auddia Announces LT350 CEO to be Interviewed on Fox Business’ Varney & Co. to Discuss Distributed Datacenter Strategy

Auddia Announces LT350 CEO to be Interviewed on Fox Business’ Varney & Co. to Discuss Distributed Datacenter Strategy

Auddia Inc. announced that its CEO, Jeff Thramann, will be interviewed on Fox Business' Varney & Co. to discuss the LT350 distributed datacenter strategy—a modular AI data center infrastructure integrated into parking lot canopies. Concurrently, Auddia plans to merge with Thramann Holdings to form McCarthy Finney, an AI native operating company, le…

Electra and Ontario Advance North America’s Critical Minerals Future with $17.5 Million Funding Agreement

Electra and Ontario Advance North America’s Critical Minerals Future with $17.5 Million Funding Agreement

Electra Battery Materials Corporation has finalized a C$17.5 million funding agreement with Invest Ontario to support the construction of North America's first cobalt sulfate refinery in Temiskaming Shores, Ontario. The refinery is expected to start commercial production by the fourth quarter of 2027, producing battery-grade cobalt sulfate and redu…

Senmiao Technology Limited Announces Name Change to Valor Energy Inc.

Senmiao Technology Limited Announces Name Change to Valor Energy Inc.

Senmiao Technology Limited has officially changed its name to Valor Energy Inc. and updated its Nasdaq ticker from AIHS to VAI. This rebranding signifies the company's strategic pivot from automobile-related services in China to developing digital infrastructure and energy projects in the U.S., focusing on AI and high-performance computing power-en…

INmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory Filings

INmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory Filings

INmune Bio has submitted regulatory filings to the European Medicines Agency seeking Orphan Drug Designation and scientific advice for Ebstrocel™, a pooled allogeneic umbilical cord-derived mesenchymal stromal cell therapy developed for recessive dystrophic epidermolysis bullosa (RDEB). These steps support the company’s planned EU Marketing Authori…

Photronics Reports Third Quarter 2026 Results

Photronics Reports Third Quarter 2026 Results

Photronics, Inc. reported its Q3 fiscal 2026 results, showing a 2.7% year-over-year revenue increase to $216 million, driven by recovering semiconductor design releases and strong fab utilization. IC revenue rose by 5%, while flat panel display revenue declined slightly. GAAP net income increased to $28.9 million ($0.49/share). The company remains …

Royalty Pharma: A Reliable Cash Engine the Market Still Misreads

Royalty Pharma: A Reliable Cash Engine the Market Still Misreads

Royalty Pharma (RPRX) is a cash-generating royalty vehicle with a diversified portfolio of commercial drugs and a growing development pipeline. At roughly $62 per share, the stock trades with an enterprise value to free cash flow of ~12x despite steady FCF of nearly $3.0B and visible catalysts (Asia expansion, Teva collaboration, new translational …

Global Mourning as Fans and Leaders React to Country Star's Death

Global Mourning as Fans and Leaders React to Country Star's Death

Fans worldwide, from heads of government to musicians and tribute performers, expressed grief after the death of the country music icon. Admirers highlighted her storytelling, cross-generational appeal and philanthropic work in literacy and healthcare. Tribute performers face immediate uncertainty about how to proceed with scheduled appearances.

Bath & Body Works Reports Second Quarter Results Exceeding Guidance and Continued Progress on Transformation

Bath & Body Works Reports Second Quarter Results Exceeding Guidance and Continued Progress on Transformation

Bath & Body Works reported Q2 2026 results exceeding guidance with net sales of $1.5 billion and adjusted EPS of $0.62, driven by growth in direct net sales and improvements in digital customer experience. Despite a slight overall sales decline, key metrics improved, prompting the company to raise its full-year 2026 earnings guidance. Management hi…

Bitdeer Announces July 2026 Production and Operations Update

Bitdeer Announces July 2026 Production and Operations Update

Bitdeer Technologies Group reports key operational highlights for July 2026, including a massive $4.7 billion, 16-year AI/HPC data center lease in Norway with potential to reach $8 billion, full commitment of their 9.5MW AI cloud facility in Malaysia with long-term contracts exceeding $800 million expected, and a 322% year-over-year increase in Bit…

Hyundai Raises 2030 Operating-Margin Objective, Shifts Toward Hybrids

Hyundai Raises 2030 Operating-Margin Objective, Shifts Toward Hybrids

Hyundai Motor Company kept its 2030 sales volume goal at 5.55 million units while increasing its operating profit margin target to above 9% for 2030. Management expects an 11% rise in operating profit, citing a stronger emphasis on hybrid vehicles. The company also detailed product timing for new hybrid and extended-range electric models and provid…

Falling Oil Eases Strain on Nervous Markets as Traders Eye Nvidia and July PCE

Falling Oil Eases Strain on Nervous Markets as Traders Eye Nvidia and July PCE

A renewed decline in global oil prices has provided a welcome cushion to jittery bond markets, even as uncertainty persists over crude flows through the Strait of Hormuz. Brent crude fell for a third day, dropping more than 2% to roughly $86 per barrel, and could register its largest weekly fall since June if sustained. Investors also await Nvidia'…